Research graph
References from First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1002/jbmr.340
10.1002/jbmr.340 · External reference
10.1152/ajprenal.90742.2008
10.1152/ajprenal.90742.2008 · External reference
10.1681/asn.2005050573
10.1681/asn.2005050573 · External reference
10.1681/asn.2007010068
10.1681/asn.2007010068 · External reference
10.1359/jbmr.0301264
10.1359/jbmr.0301264 · External reference
10.1210/jc.2006-0021
10.1210/jc.2006-0021 · External reference
[Hypophosphatemic rickets/osteomalacia. Mainly on patients with PHEX mutations]
2007 · External reference
10.1097/00005792-198911000-00002
10.1097/00005792-198911000-00002 · External reference
The changing face of hypophosphatemic disorders in the FGF‐23 era
2013 · External reference
10.1530/ec-13-0103
10.1530/ec-13-0103 · External reference
Treatment of hypophosphatemia
2009 · External reference
10.1210/jcem-52-3-463
10.1210/jcem-52-3-463 · External reference
FGF23 related hypophosphatemic rickets: current therapy and unresolved issue
2016 · External reference
10.1359/jbmr.080417
10.1359/jbmr.080417 · External reference
10.1172/jci72829
10.1172/jci72829 · External reference
10.1210/jc.2015-1551
10.1210/jc.2015-1551 · External reference
